Advances in Vitiligo: Update on Therapeutic Targets

The presentation discusses recent advances in the treatment of vitiligo, focusing on new therapeutic targets and modalities. It begins by outlining the mechanisms behind vitiligo, highlighting the role of interferon gamma and chemokines in exacerbating the condition. The speaker, whose lab specializes in vitiligo research, explains that targeting interferon gamma signaling using Janus kinase (JAK) inhibitors, such as ruxolitinib, has proven effective, leading to its FDA approval as the first treatment for repigmentation. The discussion also covers the significance of memory T cells in patient relapse after therapy, indicating that inhibiting interleukin-15, which supports these cells, could help in managing relapses. A promising new approach involving small interfering RNA (siRNA) for targeted therapy is introduced, leveraging advancements in RNA interference to degrade disease-driving mRNA in the skin. This technique, supported by a novel delivery method using ceramic stars to enhance permeation through the skin barrier, could lead to effective topical treatments for vitiligo, requiring fewer applications than traditional therapies. The culmination of these findings illustrates an exciting era of vitiligo treatment, moving from historical methods to innovative biologics and gene-targeting strategies.